Increased TNF α, IL-6 and ErbB2 mRNA expression in peripheral blood leukocytes from breast cancer patients

Medical Oncology

Volumn 31, Issue 8, 2014, Pages

  Alokail, Majed S ^a   Al Daghri, Nasser M ^a,b   Mohammed, Abdul Khader ^a   Vanhoutte, Paul ^c   Alenad, Amal ^d  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

^d UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Breast cancer; ErbB2; IL 6; TNF

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; INTERLEUKIN 6; LEPTIN; PARATHYROID HORMONE; PROTEIN P53; TUMOR NECROSIS FACTOR ALPHA; ADIPOQ PROTEIN, HUMAN; ERBB2 PROTEIN, HUMAN; IL6 PROTEIN, HUMAN; TP53 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ANTHROPOMETRIC PARAMETERS; ARTICLE; BLOOD ANALYSIS; BLOOD CELL; BLOOD SAMPLING; BODY MASS; BREAST CANCER; CANCER PATIENT; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ERYTHROLEUKEMIA; FEMALE; GENE EXPRESSION; HUMAN; LEUKOCYTE; OBESITY; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; ADOLESCENT; BLOOD; BREAST TUMOR; COMPLICATION; GENE EXPRESSION REGULATION; GENETICS; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; YOUNG ADULT;

ADIPONECTIN; ADOLESCENT; ADULT; BREAST NEOPLASMS; C-REACTIVE PROTEIN; FEMALE; GENE EXPRESSION REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-6; LEPTIN; LEUKOCYTES; MIDDLE AGED; OBESITY; OVERWEIGHT; PARATHYROID HORMONE; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL; TUMOR NECROSIS FACTOR-ALPHA; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 84902891011     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-014-0038-0     Document Type: Article

References (41)

1. Loureiro ML, Nayga RM. International dimensions of obesity and overweight related problems: an economics perspective. Am J Agric Econ. 2005;87(5):1147-53.
2. Al-Nozha MM, Al-Mazrou YY, Al-Maatouq MA, Arafah MR, Khalil MZ, Khan NB, et al. Obesity in Saudi Arabia. Saudi Med J. 2005;26(5):824-9. (Pubitemid 40903350)
3. Engström G, Hedblad B, Stavenow L, Lind P, Janzon L, Lindgärde F. Inflammation-sensitive plasma proteins are associated with future weight gain. Diabetes. 2003;52(8):2097-101. (Pubitemid 36919804)
4. Festa A, D'Agostino R Jr, Williams K, Karter A, Mayer-Davis E, Tracy R, et al. The relation of body fat mass and distribution to markers of chronic inflammation. Int J Obes Relat Metab Disord J Int Assoc Study Obes. 2001;25(10):1407.
5. Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab. 2001;280(5):E745-51.
6. Bastard JP, Jardel C, Bruckert E, Blondy P, Capeau J, Laville M, et al. Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J Clin Endocrinol Metab. 2000;85(9):3338-42.
7. Esposito K, Pontillo A, Di Palo C, Giugliano G, Masella M, Marfella R, et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women. JAMA J Am Med Assoc. 2003;289(14):1799-804. (Pubitemid 37430249)
8. Bruun JM, Verdich C, Toubro S, Astrup A, Richelsen B. Association between measures of insulin sensitivity and circulating levels of interleukin-8, interleukin-6 and tumor necrosis factoralpha. Effect of weight loss in obese men. Eur J Endocrinol. 2003;148(5):535-42. (Pubitemid 36622161)
9. Ghanim H, Aljada A, Hofmeyer D, Syed T, Mohanty P, Dandona P. Circulating mononuclear cells in the obese are in a proinflammatory state. Circulation. 2004;110(12):1564-71. (Pubitemid 39297977)
10. DeSantis C, Siegel R, Bandi P, Jemal A. Breast cancer statistics, 2011. CA Cancer J Clinicians. 2011;61:408.
11. El Saghir NS, Khalil MK, Eid T, El Kinge AR, Charafeddine M, Geara F, et al. Trends in epidemiology and management of breast cancer in developing Arab countries: a literature and registry analysis. Int J Surg. 2007;5(4):225-33. (Pubitemid 47095487)
12. Harvie M, Howell A. Energy balance adiposity and breast cancer-energy restriction strategies for breast cancer prevention. Obes Rev. 2006;7(1):33-47.
13. Lithgow D, Covington C. Chronic inflammation and breast pathology: a theoretical model. Biol Res Nurs. 2005;7(2):118-29. (Pubitemid 44289590)
14. Han C, Zhang HT, Du L, Liu X, Jing J, Zhao X, et al. Serum levels of leptin, insulin, and lipids in relation to breast cancer in China. Endocrine. 2005;26(1):19-24. (Pubitemid 41271112)
15. Tworoger SS, Eliassen AH, Kelesidis T, Colditz GA, Willett WC, Mantzoros CS, et al. Plasma adiponectin concentrations and risk of incident breast cancer. J Clin Endocrinol Metab. 2007;92(4):1510-6. (Pubitemid 46556432)
16. Heikkilä K, Ebrahim S, Lawlor DA. A systematic review of the association between circulating concentrations of C reactive protein and cancer. J Epidemiol Community Health. 2007;61(9):824-33.
17. Almquist M, Bondeson AG, Bondeson L, Malm J, Manjer J. Serum levels of vitamin D, PTH and calcium and breast cancer risk-a prospective nested case-control study. Int J Cancer. 2010;127(9):2159-68.
18. Slamon DJGW, Jones LA, et al. Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science. 1989;244(4905):707-12. (Pubitemid 19147683)
19. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science. 1991;253(5015):49-53. (Pubitemid 21917115)
20. Burczynski ME, Dorner AJ. Transcriptional profiling of peripheral blood cells in clinical pharmacogenomic studies. Pharmacogenomics. 2006;7(2):187-202.
21. Friedwald W, Levy R, Frederickson D. Estimation of plasma low density lipoprotein cholesterol concentration with use of preparative ultracentrifugation. Clin Chem. 1972;18:499-509.
22. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-[Delta] [Delta] CT method. Methods. 2001;25(4):402-8. (Pubitemid 34164012)
23. Albuquerque K, Price M, Badley R, Jonrup I, Pearson D, Blamey R, et al. Pre-treatment serum levels of tumour markers in metastatic breast cancer: a prospective assessment of their role in predicting response to therapy and survival. Eur J Surg Oncol. 1995;21(5):504-9.
24. Zhang G, Adachi I. Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma. Anticancer Res. 1999;19(2B):1427.
25. Bozcuk H, Uslu G, Samur M, YIldIz M, Özben T, Özdogan M, et al. Tumour necrosis factor-alpha, interleukin-6, and fasting serum insulin correlate with clinical outcome in metastatic breast cancer patients treated with chemotherapy. Cytokine. 2004;27(2-3):58-65. (Pubitemid 38881527)
26. Ahmad R, Al-Mass A, Atizado V, Al-Hubail A, Al-Ghimlas F, Al-Arouj M, et al. Elevated expression of the toll like receptors 2 and 4 in obese individuals: its significance for obesity-induced inflammation. J Inflamm (Lond). 2012;9:48.
27. Alokail MS, Al-Daghri NM, Al-Attas OS, Hussain T. Combined effects of obesity and type 2 diabetes contribute to increased breast cancer risk in premenopausal women. Cardiovasc Diabetol. 2009;8(1):33.
28. Hill VK, Ricketts C, Bieche I, Vacher S, Gentle D, Lewis C, et al. Genome-wide DNA methylation profiling of CpG islands in breast cancer identifies novel genes associated with tumorigenicity. Cancer Res. 2011;71(8):2988-99.
29. Sánchez J, Priego T, Picó C, Ahrens W, De Henauw S, Fraterman A, et al. Blood cells as a source of transcriptional biomarkers of childhood obesity and its related metabolic alterations: results of the IDEFICS study. J Clin Endocrinol Metab. 2012;97:E648.
30. O'Rourke R, Kay T, Lyle E, Traxler S, Deveney C, Jobe B, et al. Alterations in peripheral blood lymphocyte cytokine expression in obesity. Clin Exp Immunol. 2006;146(1):39-46. (Pubitemid 44393836)
31. Purohit A, Newman S, Reed M. The role of cytokines in regulating estrogen synthesis: implications for the etiology of breast cancer. Breast Cancer Res. 2002;4(2):65-9. (Pubitemid 34248122)
32. Berclaz G, Li S, Price K, Coates A, Castiglione-Gertsch M, Rudenstam CM, et al. Body mass index as a prognostic feature in operable breast cancer: the international breast cancer study group experience. Ann Oncol. 2004;15(6):875-84. (Pubitemid 39004342)
33. Kamel M, Shouman S, El-Merzebany M, Kilic G, Veenstra T, Saeed M, et al. Effect of tumour necrosis factor-alpha on estrogen metabolic pathways in breast cancer cells. J Cancer. 2012;3:310.
34. de Mello VDF, Kolehmainen M, Schwab U, Mager U, Laaksonen DE, Pulkkinen L, et al. Effect of weight loss on cytokine messenger RNA expression in peripheral blood mononuclear cells of obese subjects with the metabolic syndrome. Metabolism. 2008;57(2):192-9.
35. Sullivan NJ. Interleukin-6 as a potential mediator of breast cancer progression and non-melanoma skin carcinogenesis. Columbus: Ohio State University; 2009.
36. Sansone P, Storci G, Tavolari S, Guarnieri T, Giovannini C, Taffurelli M, et al. IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J Clin Invest. 2007;117(12):3988- 4002. (Pubitemid 350224108)
37. Sasser AK, Sullivan NJ, Studebaker AW, Hendey LF, Axel AE, Hall BM. Interleukin-6 is a potent growth factor for ER-α-positive human breast cancer. FASEB J. 2007;21(13):3763-70. (Pubitemid 350075164)
38. Tsiotra P, Tsigos C, Yfanti E, Anastasiou E, Vikentiou M, Psarra K, et al. Visfatin, TNF-alpha and IL-6 mRNA expression is increased in mononuclear cells from type 2 diabetic women. Horm Metab Res. 2007;39(10):758-63. (Pubitemid 350103437)
39. Kempf K, Haltern G, Futh R, Herder C, Muller-Scholze S, Gulker H, et al. Increased TNF-alpha and decreased TGF-beta expression in peripheral blood leukocytes after acute myocardial infarction. Horm Metab Res. 2006;38(5):346.
40. Swiatoniowski G, Dabrowska M, Kløaniewski T, Molenda W. Erb-2 overexpression in breast cancer]. Ginekol Pol. 2003;74(4):332.
41. Bublil EM, Yarden Y. The EGF receptor family: spearheading a merger of signaling and therapeutics. Curr Opin Cell Biol. 2007;19(2):124-34. (Pubitemid 46386405)